It is believed to be connected to or synonymous with a variety of culture-specific phenomena such as latah, koro, and amok. Classification
There are three forms of brief psychotic disorder:
BPD with a marked stressor (a.k.a. brief reactive psychosis): if BPD symptoms occur in following personal events (single or multiple) that would be expected to cause significant stress to an average individual. BPD without a marked stressor: if BPD symptoms do not occur in following personal events (single or multiple) that would be expected to cause significant stress to an average individual. BPD with postpartum onset: if onset of BPD symptoms is during pregnancy or within 4 weeks after birth. BPD with a marked stressor (brief reactive psychosis)
Brief reactive psychosis (designated since the DSM IV-TR as "brief psychotic disorder with marked stressor(s), BRP"), is the psychiatric term for psychosis which can be triggered by an extremely stressful event in the life of an individual and eventually yielding to a return to normal functioning.Brief reactive psychosis generally follows a recognisably traumatic life event like divorce or homelessness, but may be triggered by any subjective experience which appears catastrophic to the person affected. Among such stressors are the death of a loved one, professional loss such as unexpectedly losing ones job or otherwise becoming unemployed, or serious adverse changes in the patients personal life, such as the breakdown of their family through divorce, etc.
Imipenem/cilastatin/relebactam, sold under the brand name Recarbrio, is a fixed-dose combination medication used as an antibiotic. In 2019, it was approved for use in the United States for the treatment of complicated urinary tract and complicated intra-abdominal infections. It is administered via intravenous injection.The most common adverse reactions include nausea, diarrhea, headache, fever and increased liver enzymes.The most common adverse reactions observed in people treated for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) include increased aspartate/alanine aminotransferases (increased liver enzymes), anemia, diarrhea, hypokalemia (low potassium), and hyponatremia (low sodium). Medical uses
In the United States imipenem/cilastatin/relebactam is indicated for the treatment of people with complicated urinary tract infections and complicated intra-abdominal infections who have limited or no alternative treatment options. It is also indicated to treat HABP/VABP in adults 18 years of age and older.In the European Union it is indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options. History
The application for imipenem/cilastatin/relebactam was granted Qualified Infectious Disease Product (QIDP), fast track, and priority review designations by the U.S. Food and Drug Administration (FDA). The FDA granted the approval of Recarbrio to Merck & Co., Inc.The determination of efficacy of imipenem/cilastatin/relebactam was supported in part by the findings of the efficacy and safety of imipenem-cilastatin for the treatment of complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI). The contribution of relebactam to imipenem/cilastatin/relebactam was assessed based on data from in vitro studies and animal models of infection.